Quantcast

Latest Merck Stories

2014-06-03 08:33:28

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Equine Healthcare Market (Diagnostic Products, Therapeutic Products and Supplement Products) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019http://www.reportbuyer.com/pharma_healthcare/therapeutic/equine_healthcare_market_diagnostic_products_therapeutic_products_supplement_products_global_industry_analysis_size_share_growth_trends_forecast_2013_2019.html The...

2014-05-29 04:21:52

ROCKLAND, Massachusetts, May 29, 2014 /PRNewswire/ -- ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine EMD Serono pipeline products across oncology and immuno-oncology to be presented, including anti-PD-L1, c-Met...

2014-05-28 08:33:20

ROCKLAND, Mass., May 28, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Rebif(®) (interferon beta-1a) data will be presented at the 2014 Cooperative Meeting of CMSC (Consortium of Multiple Sclerosis Centers) and ACTRIMS (Americas Committee on Research & Treatment in Multiple Sclerosis), taking place from May 28 - 31, in Dallas, TX. http://photos.prnewswire.com/prnvar/20121220/SF32295LOGO-b Data from 11 study assessments will...

2014-05-20 16:26:15

National Consumer Contest Will Award One Woman $10,000 to Help Realize Her Dream of Reinvention WHITEHOUSE STATION, N.J., May 20, 2014 /PRNewswire/ -- Merck Consumer Care, the makers of OXYTROL FOR WOMEN - the first and only over-the-counter treatment for overactive bladder (OAB) - and MORE magazine announced today findings from a survey of 1,857 women 50 and over on MORE's reader panel revealing that in a perfect world 97% of them would choose a variety of ways to reinvent...

2014-05-20 08:33:00

First Chewable Tablet for Dogs Effective for 12 Weeks* Against Fleas and Ticks SUMMIT, N.J., May 20, 2014 /PRNewswire/ -- Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the U.S. Food and Drug Administration's approval of BRAVECTO(TM) (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). BRAVECTO is the first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick...

2014-05-19 23:03:46

Boston-based digital health company selected as winner of the Merck Heritage Provider Network Innovation Challenge. Boston, MA (PRWEB) May 19, 2014 Wellframe, a Boston-based company that combines mobile technology and artificial intelligence to amplify caring clinical relationships by engaging patients in personalized care plans, today announced that the organization has been named winner of the Merck | Heritage Provider Network Innovation Challenge. This award closely follows the dual...

2014-05-14 08:26:57

Blood Sugar Basics Program Launches Three Easy-to-Follow "Missions" As Many Patients with Diabetes Are Not at Their A1C Goal [Despite Ongoing Efforts] NEW YORK, May 14, 2014 /PRNewswire/ -- Today, the American College of Endocrinology (ACE), with support from Merck, known as MSD outside the United States and Canada, has launched the new Blood Sugar Basics: Get to Your Goals program to help educate the nearly 26 million Americans living with diabetes about proper blood sugar management. The...

2014-05-13 16:26:32

THOUSAND OAKS, Calif., May 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the publication of data from the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) study in the Journal of the American Medical Association (JAMA). Results from the 12-week study, which evaluated 1,896 patients with high cholesterol, showed treatment with subcutaneous evolocumab (140 mg every two weeks or 420 mg monthly) in combination with...

2014-05-13 08:33:45

BUFFALO, N.Y., May 13, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announces the addition of two key executives to its clinical leadership team reporting to Chief Medical Officer, Dr. Rudolf Kwan. Douglas Kramer MD joins Kinex as Vice President of Clinical and Regulatory Affairs and Jane Devane has joined Kinex as Director of Clinical Operations. Dr. Kramer adds significant regulatory and clinical risk management experience and was previously a Medical Officer for the United...

2014-05-06 17:08:14

Age and testing of hip bone mineral density (BDM) when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures over the next five years. Bisphosphonates can reduce the risk of hip and spine fractures. But recent concerns about safety issues, including osteonecrosis of the jaw, atypical femoral fractures and esophageal cancer, have increased interest in interrupting or stopping bisphosphonate therapy after several years of treatment. This study...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related